Skip to main content
. 2022 Jan 17;9:813503. doi: 10.3389/fcell.2021.813503

FIGURE 5.

FIGURE 5

Inhibition of DOT1L methyltransferase activity with administration of EPZ-5676. Selective DOT1L methyltransferase inhibitor, EPZ-5676 (EPZ) was dissolved in 9:1, saline:ethanol and administered (30 μg/g body weight, intraperitoneally, twice daily) into 4-week old mice for 3 weeks (A). Age-matched control mice (Cont.) mice were injected with 9:1 saline:ethanol for the same duration. After 3 weeks, of EPZ-5676 or vehicle-treated mice were euthanized, and blood and bone marrow were collected. EPZ treatment significantly reduced H3K79 di-methylation in bone marrow cells (B,C). However, hemoglobin (Hb) levels were not decreased after EPZ treatment (D), and a peripheral blood film showed apparently minimal-to-no changes in the blood (E,F). RT-PCR analysis of expression of genes involved in blood development in bone marrow cells from Cont. or EPZ-treated mice showed no significant changes (G–L). Data presented as mean ± SEM, n ≥ 6, and * indicates p ≦ 0.05.